Based on patterns of recurrence-free survival (RFS) over time in some studies, the researchers determined that 5-year RFS may be a suitable surrogate for measuring cure. In considering outcomes for ...

The FDA recently approved a pretzel-shaped implant that helps some bladder cancer patients keep their bladder. Dr. Chris ...

Discover how the ALYREF biomarker predicts bladder cancer aggressiveness and boosts immunotherapy response. Find out more ...

Bladder cancer is the ninth most common cancer in the world, the fourth most common cancer in men, and the 11th most common ...

The findings showed that disease progression not only worsens patient outcomes but also significantly increases overall healthcare costs. Late-stage disease and post-recurrence cystectomy were ...

A supervised exercise program helped patients with advanced breast cancer live longer, according to a study presented at the Advanced Breast Cancer Conference.

The health impacts of men losing their Y chromosome from their cells are increasingly coming to light, with the loss playing ...

Jefferies London Healthcare Conference 2025 November 18, 2025 8:00 AM ESTCompany ParticipantsSteve Chapman - CEO & ...

The most common adverse events reported in the neoadjuvant and adjuvant pembrolizumab plus enfortumab vedotin arm were pruritus, alopecia, diarrhea, fatigue and anemia. No new safety signals were ...

DPI-4452 targets CAIX in tumors, offering noninvasive diagnostic potential for ccRCC with favorable tolerability. The agent is part of a theranostic pair wi ...

Q3 2025 Earnings Call Transcript November 13, 2025 Relmada Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

Aura Biosciences advances bel-sar in eye cancers with promising signals, facing potential cash needs before the Phase 3 ...